Reckitt Benckiser Group (OTCMKTS:RBGLY - Get Free Report) was downgraded by investment analysts at Sanford C. Bernstein from a "strong-buy" rating to a "hold" rating in a report issued on Monday, Zacks.com reports.
RBGLY has been the topic of a number of other reports. JPMorgan Chase & Co. downgraded Reckitt Benckiser Group from an "overweight" rating to a "neutral" rating in a research note on Thursday, August 29th. UBS Group raised Reckitt Benckiser Group to a "strong-buy" rating in a report on Wednesday, September 18th. Citigroup raised Reckitt Benckiser Group to a "strong-buy" rating in a report on Tuesday, October 1st. Finally, Barclays raised Reckitt Benckiser Group to a "strong-buy" rating in a report on Friday, October 4th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Reckitt Benckiser Group has a consensus rating of "Moderate Buy".
Check Out Our Latest Stock Report on RBGLY
Reckitt Benckiser Group Trading Down 2.7 %
Shares of RBGLY traded down $0.35 during mid-day trading on Monday, hitting $12.54. The company's stock had a trading volume of 1,982,779 shares, compared to its average volume of 912,414. The company has a quick ratio of 0.47, a current ratio of 0.69 and a debt-to-equity ratio of 0.97. Reckitt Benckiser Group has a 1-year low of $10.24 and a 1-year high of $15.03. The firm has a 50-day simple moving average of $12.24 and a 200 day simple moving average of $11.57.
Reckitt Benckiser Group Company Profile
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
See Also
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
